Skip to Main Content
Contribute Try STAT+ Today

Naomi Fried has watched the same plot unfold over and over again: A digital health startup pitches software to accelerate drug discovery, track medication use, or identify patients for clinical trials. But initial interest from pharma executives quickly fades. They stop returning emails, often with no explanation.

But if the reasons are mysterious to startups, they are not to Fried, who has spent her career driving technology innovation at Biogen, Boston Children’s Hospital, and Kaiser Permanente. She said the startups are simply misunderstanding their audience and the business concerns that drive decision-making.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.